ExodusPoint Capital Management LP Sells 122,412 Shares of LivaNova PLC (NASDAQ:LIVN)

ExodusPoint Capital Management LP lowered its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 19.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 520,623 shares of the company’s stock after selling 122,412 shares during the period. ExodusPoint Capital Management LP owned approximately 0.96% of LivaNova worth $24,110,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of LIVN. Central Pacific Bank Trust Division grew its holdings in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares during the period. Vestcor Inc bought a new position in shares of LivaNova during the fourth quarter worth $204,000. Captrust Financial Advisors bought a new position in shares of LivaNova during the third quarter worth $217,000. Inceptionr LLC bought a new stake in shares of LivaNova in the 4th quarter valued at $217,000. Finally, Sanctuary Advisors LLC acquired a new stake in LivaNova during the 3rd quarter worth $219,000. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Up 1.2 %

Shares of LIVN stock opened at $39.50 on Thursday. The firm’s fifty day moving average price is $43.94 and its two-hundred day moving average price is $48.29. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.48. The firm has a market capitalization of $2.15 billion, a P/E ratio of 94.05 and a beta of 1.10.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on LIVN shares. Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group lowered their target price on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Stifel Nicolaus cut their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. Finally, StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 25th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.